Advice
Following a full submission
teriparatide (Forsteo®) is not recommended for use within NHS Scotland for the treatment of osteoporosis in men at increased risk of fracture.
Teriparatide was associated with a greater increase in lumbar spine bone mineral density than placebo.
The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice94KB (PDF)
Medicine details
- Medicine name:
- teriparatide (Forsteo)
- SMC ID:
- 490/08
- Indication:
- For the treatment of osteoporosis in men at increased risk of fracture.
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 11 August 2008